Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 13/20 | 0.57 |
| ▸ | MKNK1 | Q9BUB5 | 3/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.38 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.38 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.38 |
| ▸ | SLC22A11 | Q9NSA0 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4204959 | 0.89 | TRPV1 (0.67) | TRPV1MKNK1 | |
| SCHEMBL4202162 | 0.89 | TRPV1 (0.56) | TRPV1MKNK1 | |
| SCHEMBL3261801 | 0.88 | TRPV1 (0.57) | TRPV1MKNK1 | |
| SCHEMBL4200822 | 0.87 | MKNK1 (0.61) | TRPV1MKNK1 | |
| SCHEMBL4215390 | 0.87 | TRPV1 (0.68) | TRPV1MKNK1 | |
| SCHEMBL3259960 | 0.86 | TRPV1 (0.56) | TRPV1MKNK1 | |
| SCHEMBL4206750 | 0.86 | TRPV1 (0.53) | TRPV1MKNK1 | |
| SCHEMBL4205495 | 0.84 | TRPV1 (0.59) | TRPV1MKNK1 | |
| SCHEMBL3122851 | 0.83 | TRPV1 (0.72) | TRPV1MKNK1 | |
| SCHEMBL4209953 | 0.83 | TRPV1 (0.61) | TRPV1MKNK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160376291-A1 | IMIDAZOLO-, OXAZOLO-, AND THIAZOLOPYRIMIDINE MODULATORS OF TRPV1 | JANSSEN PHARMACEUTICA NV (BE) | 2016-12-29 | — | — | US | claimed |
| EP-2224929-B1 | IMIDAZOLO-, OXAZOLO-, AND THIAZOLOPYRIMIDINE MODULATORS OF TRPV1 | JANSSEN PHARMACEUTICA NV (BE) | 2016-05-04 | — | — | EP | claimed |
| US-20140107098-A1 | IMIDAZOLO-, OXAZOLO-, AND THIAZOLOPYRIMIDINE MODULATORS OF TRPV1 | JANSSEN PHARMACEUTICA NV (US) | 2014-04-17 | — | — | US | claimed |
| US-20130005687-A1 | IMIDAZOLO-, OXAZOLO-, AND THIAZOLOPYRIMIDINE MODULATORS OF TRPV1 | BRANSTETTER BRYAN JAMES (US) | 2013-01-03 | — | — | US | claimed |
| US-8288397-B2 | Imidazolo-, oxazolo-, and thiazolopyrimidine modulators of TRPV1 | JANSSEN PHARMACEUTICA NV (BE) | 2012-10-16 | — | — | US | claimed |
| US-20090156599-A1 | Imidazolo-, oxazolo-, and thiazolopyrimidine modulators of TRPV1 | JANSSEN PHARMACEUTICA NV (BE) | 2009-06-18 | — | — | US | claimed |
| US-20160376291-A1 | IMIDAZOLO-, OXAZOLO-, AND THIAZOLOPYRIMIDINE MODULATORS OF TRPV1 | JANSSEN PHARMACEUTICA NV (BE) | 2016-12-29 | — | — | US | disclosed |
| US-9440978-B2 | Imidazolo-, oxazolo-, and thiazolopyrimidine modulators of TRPV1 | JANSSEN PHARMACEUTICA NV (BE) | 2016-09-13 | — | — | US | disclosed |
| US-9440978-B2 | Imidazolo-, oxazolo-, and thiazolopyrimidine modulators of TRPV1 | JANSSEN PHARMACEUTICA NV (BE) | 2016-09-13 | — | — | US | disclosed |
| EP-2224929-B1 | IMIDAZOLO-, OXAZOLO-, AND THIAZOLOPYRIMIDINE MODULATORS OF TRPV1 | JANSSEN PHARMACEUTICA NV (BE) | 2016-05-04 | — | — | EP | disclosed |
| US-20140107098-A1 | IMIDAZOLO-, OXAZOLO-, AND THIAZOLOPYRIMIDINE MODULATORS OF TRPV1 | JANSSEN PHARMACEUTICA NV (US) | 2014-04-17 | — | — | US | disclosed |
| US-20140107098-A1 | IMIDAZOLO-, OXAZOLO-, AND THIAZOLOPYRIMIDINE MODULATORS OF TRPV1 | JANSSEN PHARMACEUTICA NV (US) | 2014-04-17 | — | — | US | disclosed |
| US-8637527-B2 | Imidazolo-, oxazolo-, and thiazolopyrimidine modulators of TRPV1 | JANSSEN PHARMACEUTICA NV (BE) | 2014-01-28 | — | — | US | disclosed |
| US-8288397-B2 | Imidazolo-, oxazolo-, and thiazolopyrimidine modulators of TRPV1 | JANSSEN PHARMACEUTICA NV (BE) | 2012-10-16 | — | — | US | disclosed |
| US-8288397-B2 | Imidazolo-, oxazolo-, and thiazolopyrimidine modulators of TRPV1 | JANSSEN PHARMACEUTICA NV (BE) | 2012-10-16 | — | — | US | disclosed |
| US-8288397-B2 | Imidazolo-, oxazolo-, and thiazolopyrimidine modulators of TRPV1 | JANSSEN PHARMACEUTICA NV (BE) | 2012-10-16 | — | — | US | disclosed |
| WO-2009078999-A1 | IMIDAZOLO-, OXAZOLO-, AND THIAZOLOPYRIMIDINE MODULATORS OF TRPV1 | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-06-25 | — | — | WO | disclosed |
| US-20090156599-A1 | Imidazolo-, oxazolo-, and thiazolopyrimidine modulators of TRPV1 | JANSSEN PHARMACEUTICA NV (BE) | 2009-06-18 | — | — | US | disclosed |
| US-20090156599-A1 | Imidazolo-, oxazolo-, and thiazolopyrimidine modulators of TRPV1 | JANSSEN PHARMACEUTICA NV (BE) | 2009-06-18 | — | — | US | disclosed |
| US-20090156599-A1 | Imidazolo-, oxazolo-, and thiazolopyrimidine modulators of TRPV1 | JANSSEN PHARMACEUTICA NV (BE) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160376291-A1 | IMIDAZOLO-, OXAZOLO-, AND THIAZOLOPYRIMIDINE MODULATORS OF TRPV1 | TRPV1, TRPA1, TRPV4 | TRPV1 1/4885MKNK1 874/4885EPHX2 1937/4885 |
| US-20130005687-A1 | IMIDAZOLO-, OXAZOLO-, AND THIAZOLOPYRIMIDINE MODULATORS OF TRPV1 | TRPV1, TRPA1, TRPV4 | TRPV1 1/4885MKNK1 874/4885EPHX2 1937/4885 |
| US-20140107098-A1 | IMIDAZOLO-, OXAZOLO-, AND THIAZOLOPYRIMIDINE MODULATORS OF TRPV1 | TRPV1, TRPA1, TRPV4 | TRPV1 1/4885MKNK1 874/4885EPHX2 1937/4885 |
| US-20090156599-A1 | Imidazolo-, oxazolo-, and thiazolopyrimidine modulators of TRPV1 | TRPV1, TRPA1, TRPV4 | TRPV1 1/4885MKNK1 874/4885EPHX2 1937/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.